| Literature DB >> 31601181 |
Obando Evelyn1, Fernández-Sarmiento Jaime2, Montoya David1, Acevedo Lorena1, Arroyave Jenifer3, Gamboa Oscar4.
Abstract
BACKGROUND: Acute respiratory infections (ARIs) are one of the main causes of morbidity and mortality in children. Viruses are the main etiological agents, and their behavior tends to be seasonal and vary by geographical location. Human metapneumovirus (HMPV) has recently been described as a cause of severe acute respiratory infection and its prevalence and clinical behavior in children at moderate altitudes is unknown.Entities:
Keywords: Children; Pneumonia; Respiratory syncytial virus; Viral infection
Year: 2019 PMID: 31601181 PMCID: PMC6785857 DOI: 10.1186/s12887-019-1734-x
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Clinical characteristics of human metapneumovirus infection in hospitalized children
| Characterístic | HMPV positive group ( | HMPV negative group ( | Total ( |
|
|---|---|---|---|---|
| Age (months) | Median: 43 (IQR 9–101) | Median: 21 (IQR 6–57) | Median: 21 (IQR: 7–60) |
|
| Sex |
| |||
| Male | 12 (54.6%) | 225 (56.5%) | 237 (56.4%) | |
| Female | 10 (45.4%) | 173 (43.5%) | 183 (43.6%) | |
| Comorbidities | ||||
| Kidney disease | 4 (18.2%) | 36 (9%) | 40 (9.5%) |
|
| Liver disease | 3 (13.6%) | 50 (12.6%) | 53 (12.6%) |
|
| Heart disease | 1 (4.5%) | 67 (16.8%) | 68 (16.2%) |
|
| Transplant | 2 (9.1%) | 45 (11.3%) | 47 (11.2%) |
|
| Prematurity | 3 (13.6%) | 52 (13.1%) | 55 (13.1%) |
|
| Bronchopulmonary dysplasia | 2 (9.1%) | 50 (12.6%) | 52 (12.4%) |
|
| Metabolic diseases | 1 (4.5%) | 26 (6.5%) | 27 (6.4%) |
|
| Primary immunodeficiency | 1 (4.5%) | 39 (9.8%) | 40 (9.5%) |
|
| Cancer | 4 (18.2%) | 46 (11.6%) | 50 (11.9%) |
|
| Any comorbidity | 15 (68.2%) | 237 (59.5%) | 252 (60%) |
|
| Nutritional status |
| |||
| Severe malnutrition | 4 (18.2%) | 65 (13.3%) | 69 (16.4%) | |
| Malnutrition | 4 (18.2%) | 78 (19.6%) | 82 (19.5%) | |
| Normal | 13 (59.1%) | 244 (61.3%) | 257 (61.2%) | |
| Overweight | 1 (4.5%) | 10 (2.7%) | 11 (2.6%) | |
| Obesity | 0 (0%) | 1 (0.3%) | 1 (0.3%) | |
| Diagnoses |
| |||
| Croup | 0 (0%) | 7 (1.8%) | 7 (1.7%) | |
| Bronchiolitis | 3 (13.6%) | 74 (18.6%) | 77 (18.3%) | |
| Pneumonia | 10 (45.5%) | 200 (50.3%) | 210 (50%) | |
| Asthma attack | 0 (0%) | 18 (4.5%) | 18 (4.3%) | |
| Recurrent wheezing | 2 (9.1%) | 14 (3.5%) | 16 (3.8%) | |
| Laryngitis | 0 (0%) | 4 (1%) | 4 (0.9%) | |
| ARDS | 3 (13.6%) | 24 (6%) | 27 (6.4%) | |
| Rhinopharyngitis | 4 (18.2%) | 55 (13.8%) | 59 (14.1%) | |
| Sinusitis | 0 (0%) | 1 (0.3%) | 1 (0.3%) | |
| Tracheitis | 0 (0%) | 1 (0.3%) | 1 (0.3%) | |
| Type of infection |
| |||
| HAI | 5 (22.7%) | 122 (30.6%) | 127 (30.2%) | |
| Community | 17 (77.3%) | 276 (69.4%) | 293 (69.8%) | |
| Bacterial coinfection | 6 (27.3%) | 151 (38%) | 157 (37.4%) |
|
| Antibiotics |
| |||
| Yes | 17 (77.3%) | 281 (70.6%) | 298 (71%) | |
| No | 5 (22.7%) | 117 (29.4%) | 122 (29%) | |
| Viral coinfection | 5 (22.7%) | 56 (14%) | 61 (14.5%) |
|
| Length of hospital stay | Median: 10.5 days (IQR 6–26) | Median: 12 days (IQR 6–27) | Median: 12 days (IQR: 6–27) |
|
Respiratory multiplex RT-PCR isolates
| Multiplex RT-PCR isolation | |
|---|---|
| Human rhinovirus/enterovirus | 125 (30%) |
| Respiratory syncytial virus | 80 (19%) |
| Parainfluenza virus 3 | 31 (7.4%) |
| Adenovirus | 24 (5.7%) |
| Human metapneumovirus | 22 (5.2%) |
| Mycoplasma pneumoniae | 14 (3.3%) |
| Influenza A/H31 | 10 (2.3%) |
| Coronavirus NL63 | 6 (1.4%) |
| Parainfluenza virus 1 | 5 (1.2%) |
| Influenza A/H1–2009 | 5 (1.2%) |
| Parainfluenza virus 4 | 4 (1%) |
| Coronavirus OC43 | 4 (1%) |
| Influenza B | 3 (0.7%) |
| Coronavirus HKU1 | 3 (0.7%) |
| Coronavirus 229E | 2 (0.5%) |
| Parainfluenza virus 2 | 2 (0.5%) |
| Influenza A | 1 (0.2%) |
| Chlamydia pneumoniae | 1 (0.2%) |
| Influenza A/H1 | 0 (0%) |
| Bordetella pertussis | 0 (0%) |
| Undetected | 129 (30.7%) |
| Coinfections | 61 (14.5%) |
Clinical characteristics of human metapneumovirus infection in the intensive care unit
| Characteristic | HMPV positive group ( | HMPV negative group ( | Total ( |
|
|---|---|---|---|---|
| PIM 2 | Median: 0.6% (IQR 0.3–1%) | Median: 0.9% (IQR 0.3–2.8%) | Median: 0.9% (IQR: 0.3–2.8%) |
|
| Length of PICU stay | Median: 7 days (IQR 4–14.5) | Median: 6 days (IQR 3–15) | Median: 6 days (IQR 3–15) |
|
| Mortality | 3 (13.6%) | 27 (6.8%) | 30 (7.1%) |
|
| Type of Ventilation |
| |||
| Invasive | 7 (31.8%) | 83 (20.9%) | 90 (21.4%) | |
| Non-invasive | 1 (4.6%) | 10 (2.5%) | 11 (2.6%) | |
| HFNC | 4 (18.2%) | 70 (17.9%) | 74 (17.6%) | |
| Nasal cannula | 5 (22.7%) | 134 (33.7%) | 139 (33%) | |
| Ventury | 0 (0%) | 8 (2.01%) | 8 (1.9%) | |
| None | 5 (22.7%) | 93 (23.4%) | 98 (23.3%) | |
| Days on Mechanical Ventilation | Median: 7 days (IQR 3–17) | Median: 6 days (IQR 3–14) | Median: 6 days (IQR 3–17) |
|
HMPV Human metapneumovirus, PIM 2 Pediatric Index Mortality 2 Scale, PICU Pediatric intensive care unit, HFNC High flow nasal cannula
Severe HMPV infection
| HMPV positive | PICU ( | NO PICU ( |
|
|---|---|---|---|
| Age |
| ||
| Under 1 year | 5 (41.6%) | 2 (20%) | |
| 1–2 years | 2 (16.7%) | 0 (0%) | |
| 2–5 years | 2 (16.7%) | 4 (40%) | |
| Over 5 years | 3 (25%) | 4 (40%) | |
| Sex |
| ||
| Male | 8 (66.7%) | 4 (40%) | |
| Female | 4 (33.3%) | 6 (60%) | |
| Comorbidities | |||
| None | 2 (16.7%) | 2 (20%) |
|
| Kidney disease | 2 (16.7%) | 2 (20%) |
|
| Liver disease | 2 (16.7%) | 1 (10%) |
|
| Heart disease | 1 (8.3%) | 0 (0%) |
|
| Transplant | 0 (0%) | 2 (20%) |
|
| Prematurity | 3 (25%) | 0 (0%) |
|
| Bronchopulmonary dysplasia | 2 (16.7%) | 0 (0%) |
|
| Metabolic disease | 1 (8.3%) | 0 (0%) |
|
| Primary immunodeficiency | 1 (8.3%) | 0 (0%) |
|
| Cancer | 0 (0%) | 4 (40%) | |
| Nutritional status |
| ||
| Severe malnutrition | 3 (25%) | 1 (10%) | |
| Malnutrition | 2 (16.7%) | 2 (20%) | |
| Normal | 6 (50%) | 7 (70%) | |
| Overweight | 1 (8.3%) | 0 (0%) | |
| Obesity | 0 (0%) | 0 (0%) | |
| Diagnoses |
| ||
| Pneumonia | 7 (58.3%) | 3 (30%) | |
| ARDS | 3 (25%) | 0 (0%) | |
| Bronchiolitis | 1 (8.3%) | 2 (20%) | |
| Recurrent wheezing | 1 (8.3%) | 1 (10%) | |
| Rhinopharyngitis | 0 (0%) | 4 (40%) | |
| Viral coinfection | 4 (33.3%) | 1 (10%) |
|
| Bacterial coinfection | 6 (50%) | 1 (10%) |
|
Fig. 1Distribution of human metapneumovirus, rhinovirus and respiratory syncytial infections as related to rainfall during 2016–2017
Fig. 2Dispersion diagram of the Metapneumovirus infection and rainfall peaks